What Is Caplyta, and Why Does It Matter? Caplyta (lumateperone) is a once-daily oral medicine now approved to be used with antidepressants to treat major depressive disorder (MDD) in adults. It ...
In older adults with asthma, major depressive disorder was linked to poorer control and quality of life, partly via negative ...
Clinical data further supports the effectiveness of EXOMIND. In a recent IRB-approved clinical trial, 83% of patients diagnosed with depression reported feeling less depressed three months after their ...
Please provide your email address to receive an email when new articles are posted on . The clearance was based on a study in which adults with MDD used Rejoyn or a sham treatment app for 6 weeks. One ...
Patients with asthma and major depressive disorder had more negative beliefs about their asthma, worse treatment adherence and more ED visits, according to data published in The Journal of Allergy and ...
Current Primary Outcome Measures •Percentage of Participants with Response (>=50 Percent improvement in MADRS total score from baseline) at Week 26 [ Time Frame: Week 26 ] -- Responders are defined as ...
A new analysis included more than 110,000 adults with major depressive disorder (MDD) and treatment-resistant depression (TRD). Patients with TRD had total healthcare costs 1.5 times higher than those ...
IEEE Spectrum on MSN
At-home brain stimulation for depression is just the start
Flow’s headset is the first tDCS device approved by the FDA ...
How light deprivation, disrupted routines, and severe winter weather are impacting mental health across all ages LAS ...
About The Study: In this longitudinal cohort study of older drivers, adults with major depressive disorder demonstrated distinct and riskier driving behaviors than those in the control group without ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results